ASH Annual Meeting
ASH Annual Meeting 9 – 12 December 2023 San Diego, CA Visit conference website
This author has not written his bio yet.
But we are proud to say that Renee Hansen contributed 93 entries already.
ASH Annual Meeting 9 – 12 December 2023 San Diego, CA Visit conference website
ESH: 6th International Conference on Acute Myeloid Leukaemia: “Molecular and Translational”: Advances in Biology and Treatment 29 – 31 October 2023Estoril, PortugalVisit conference website
AACR-NCI-EORTC – International Conference on Molecular Targets and Cancer Therapeutics 11 – 15 October 2023 Boston, MA Visit conference website
View Presentation: Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis Abstract: Background: Cedazuridine (CED), a cytidine deaminase (CDA) inhibitor allows oral availability of decitabine (DEC); 5 daily doses of the fixed-dose combination (FDC) of 35 mg DEC/100 mg CED […]
View Presentation: Efficacy and Safety of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subpopulation from Phase 2 and ASCERTAIN Phase 3 Studies Abstract: Background: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disease characterized by persistent monocytosis, splenomegaly, and both dysplastic and myeloproliferative changes in the bone marrow. Hypomethylating agents (HMAs) are approved for […]
View Presentation: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES Abstract: Background: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disease characterized by persistent monocytosis, splenomegaly, and both dysplastic and myeloproliferative changes in the bone marrow. Hypomethylating agents are approved for CMML […]
View Presentation: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS Abstract: Background: Cedazuridine(CED),a cytidine deaminase(CDA) inhibitor allows oral availability of decitabine(DEC) and 5 daily doses of the fixed-dose combination of 35 mg DEC/100 mg CED standard dose(SD) provides equivalent […]
17th International Conference on Malignant Lymphoma (ICML) 13 – 17 June 2023 Lugano, Switzerland Visit conference website
EHA Hybrid Congress 2023 8 – 11 June 2023 Frankfurt, Germany Visit the conference website
ASCO Annual Meeting 2 – 6 June 2023 Chicago, IL Visit the conference website